Joshua S Barclay1, Justine E Owens, Leslie J Blackhall. 1. Division of General Internal Medicine, Geriatrics, and Palliative Care, Department of Medicine, University of Virginia, PO Box 800744, Charlottesville, VA, 22908, USA, jsb8y@virginia.edu.
Abstract
PURPOSE: The use of opioids for management of cancer-related pain has increased significantly and has been associated with a substantial rise in rates of substance abuse and diversion. There is a paucity of data not only on the prevalence of substance abuse in cancer patients, but also for issues of drug use and diversion in family caregivers. This study aimed to evaluate the frequency of risk factors for substance abuse and diversion, and abnormal urine drug screens in cancer patients receiving palliative care. METHODS: A retrospective chart review was performed for patients with cancer who were seen in the University of Virginia Palliative Care Clinic during the month of September 2012. We evaluated Opioid Risk Tool variables and total scores, insurance status, and urine drug screen results. RESULTS: Of the 114 cancer patients seen in September 2012, the mean Opioid Risk Tool score was 3.79, with 43% of patients defined as medium to high risk. Age (16-45 years old, 23%) and a personal history of alcohol (23%) or illicit drugs (21%) were the most common risk factors identified. We obtained a urine drug screen on 40% of patients, noting abnormal findings in 45.65%. CONCLUSIONS: Opioids are an effective treatment for cancer-related pain, yet substantial risk for substance abuse exits in the cancer population. Screening tools, such as the Opioid Risk Tool, should be used as part of a complete patient assessment to balance risk with appropriate relief of suffering.
PURPOSE: The use of opioids for management of cancer-related pain has increased significantly and has been associated with a substantial rise in rates of substance abuse and diversion. There is a paucity of data not only on the prevalence of substance abuse in cancerpatients, but also for issues of drug use and diversion in family caregivers. This study aimed to evaluate the frequency of risk factors for substance abuse and diversion, and abnormal urine drug screens in cancerpatients receiving palliative care. METHODS: A retrospective chart review was performed for patients with cancer who were seen in the University of Virginia Palliative Care Clinic during the month of September 2012. We evaluated Opioid Risk Tool variables and total scores, insurance status, and urine drug screen results. RESULTS: Of the 114 cancerpatients seen in September 2012, the mean Opioid Risk Tool score was 3.79, with 43% of patients defined as medium to high risk. Age (16-45 years old, 23%) and a personal history of alcohol (23%) or illicit drugs (21%) were the most common risk factors identified. We obtained a urine drug screen on 40% of patients, noting abnormal findings in 45.65%. CONCLUSIONS: Opioids are an effective treatment for cancer-related pain, yet substantial risk for substance abuse exits in the cancer population. Screening tools, such as the Opioid Risk Tool, should be used as part of a complete patient assessment to balance risk with appropriate relief of suffering.
Authors: Hammam Akbik; Stephen F Butler; Simon H Budman; Katherine Fernandez; Nathaniel P Katz; Robert N Jamison Journal: J Pain Symptom Manage Date: 2006-09 Impact factor: 3.612
Authors: S D Passik; K L Kirsh; M V McDonald; S Ahn; S M Russak; L Martin; B Rosenfeld; W S Breitbart; R K Portenoy Journal: J Pain Symptom Manage Date: 2000-04 Impact factor: 3.612
Authors: Edward Michna; Edgar L Ross; Wilfred L Hynes; Srdjan S Nedeljkovic; Sharonah Soumekh; David Janfaza; Diane Palombi; Robert N Jamison Journal: J Pain Symptom Manage Date: 2004-09 Impact factor: 3.612
Authors: Stephen F Butler; Kathrine Fernandez; Christine Benoit; Simon H Budman; Robert N Jamison Journal: J Pain Date: 2008-01-22 Impact factor: 5.820
Authors: C S Cleeland; R Gonin; A K Hatfield; J H Edmonson; R H Blum; J A Stewart; K J Pandya Journal: N Engl J Med Date: 1994-03-03 Impact factor: 91.245
Authors: Robert A Swarm; Amy Pickar Abernethy; Doralina L Anghelescu; Costantino Benedetti; Sorin Buga; Charles Cleeland; Oscar A Deleon-Casasola; June G Eilers; Betty Ferrell; Mark Green; Nora A Janjan; Mihir M Kamdar; Michael H Levy; Maureen Lynch; Rachel M McDowell; Natalie Moryl; Suzanne A Nesbit; Judith A Paice; Michael W Rabow; Karen L Syrjala; Susan G Urba; Sharon M Weinstein; Mary Dwyer; Rashmi Kumar Journal: J Natl Compr Canc Netw Date: 2013-08 Impact factor: 11.908
Authors: Kevin T Liou; Tony K W Hung; Salimah H Meghani; Andrew S Epstein; Q Susan Li; Sally A D Romero; Roger B Cohen; Jun J Mao Journal: Pain Med Date: 2019-10-01 Impact factor: 3.750
Authors: Sherri Rauenzahn; Adam Sima; Brian Cassel; Danielle Noreika; Teny Henry Gomez; Lynn Ryan; Carl E Wolf; Luke Legakis; Egidio Del Fabbro Journal: Support Care Cancer Date: 2017-01-25 Impact factor: 3.603
Authors: Nalini Vadivelu; Alice M Kai; Gopal Kodumudi; Dan Haddad; Vijay Kodumudi; Niketh Kuruvilla; Alan David Kaye; Richard D Urman Journal: Curr Pain Headache Rep Date: 2018-03-19
Authors: A Carmona-Bayonas; P Jiménez-Fonseca; E Castañón; A Ramchandani-Vaswani; R Sánchez-Bayona; A Custodio; D Calvo-Temprano; J A Virizuela Journal: Clin Transl Oncol Date: 2016-07-21 Impact factor: 3.405